PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.
Table 1: Smoking Cessation Agents

**Formulary Agents:**
- Varenicline tablets (brand name Chantix)
- Bupropion SR tablets (brand name Zyban and generics)
- Nicotine nasal spray (brand name Nicotrol NS)
- Nicotine inhalation (brand name Nicotrol)
- Nicotine transdermal (brand names Nicoderm CQ and Habitrol)
- Nicotine Gum (brand names Nicorette, Nicorelief, and generics)
- Nicotine Lozenge (brand names Nicorette)

**Non-Formulary:** None

**Recommended implementation period for program:** 60 days upon signing of the final rule

Table 2: Newer Sedative Hypnotics

**Formulary:**
- Zolpidem IR tablets (brand name Ambien and generics)
- Zaleplon capsules (brand name Sonata and generics)

**Formulary with documented trial or contraindication for Zolpidem IR (Ambien) and Zaleplon (Sonata):**
- Zolpidem controlled release tablets (brand name Ambien CR and generics)
- Doxepin tablets (brand name Silenor)
- Eszopiclone tablets (brand name Lunesta)

**Non-formulary with a documented trial or contraindication for Zolpidem IR (Ambien) and Zaleplon (Sonata):**
- Ramelteon tablets (brand name Rozerem)
- Zolpidem sublingual tablets (brand name Edluar)

**Not covered:** Zolpidem spray (brand name Zolpimist) declined to participate in the FSS/VHCA pricing program

**Recommended implementation period:** 60 days
Figure 1: Newer Sedative Hypnotics — 30-Day Equivalents in All POS
Table 3: Non-opioid Pain Syndrome Agents

**GABA Analog Subclass**

Formulary:Gabapentin immediate release (brand name Neurontin and generics)  
Non-formulary with a documented trial or contraindication for gapentin IR  
(Neurontin/generics):
  - Pregabalin (brand name Lyrica)
  - Gabapentin enacarbil (brand name Horizant)
  - Gabapentin extended release (brand name Gralise)

Implementation Plan: N/A

Figure 2: Non-opioid Pain Syndrome Agents — Utilization in 30-Day Equivalents in All POS
Table 4: Table of Implementation Status of UF Recommendations/Decisions Summary Table

<table>
<thead>
<tr>
<th>Meeting</th>
<th>Drug Class</th>
<th>Non-Formulary Medications</th>
<th>Total Beneficiaries Affected (# of patients affected)</th>
<th>Beneficiaries Affected by POS</th>
<th>Implementation Plan</th>
<th>Step Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2012</td>
<td>Newer Sedative Hypnotics</td>
<td>Zolpidem spray (Zolpimist)</td>
<td>82</td>
<td>0</td>
<td>72</td>
<td>10 60 days</td>
</tr>
<tr>
<td></td>
<td>Non-opioid Pain Syndrome Agents</td>
<td>Gabapentin enacarbil (Horizant)</td>
<td>1216</td>
<td>14</td>
<td>1009</td>
<td>193 30 days Must try gabapentin IR (Neurontin/generics)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gabapentin extended release (Gralise)</td>
<td>527</td>
<td>3</td>
<td>485</td>
<td>39</td>
</tr>
</tbody>
</table>